Synergistic N/Mn Codoping Deagglomerate Carbon Coating of LiFePO₄/C To Boost Electrochemical Performance by Yu-Wei Wang (1749115)

“…Consequently, this strategy effectively improves the rate capability (119 mA h g^–1 at 10 C) while maintaining excellent cycling performance (88% capacity retention over 600 cycles at 5 C). …”

Higher expression of proinflammatory cytokines, co-stimulatory molecules and subsequent antigen presentation in P1 DCs that have captured <i>LdCen^-/-</i> infected neutro... by Parna Bhattacharya (316881)

Image_1_CD8+ T-Cell Epitope Variations Suggest a Potential Antigen HLA-A2 Binding Deficiency for Spike Protein of SARS-CoV-2.tif by Congling Qiu (11957873)

“…Meanwhile, n-Sp1 epitope variant 5L>F significantly decreased the proportion of specific T-cell activation; n-Sp1 epitope 8L>V variant showed significantly reduced binding to HLA-A*02:01 and decreased proportion of n-Sp1-specific CD8⁺ T cell, which potentially contributes to the immune escape of SARS-CoV-2. …”

Image_3_CD8+ T-Cell Epitope Variations Suggest a Potential Antigen HLA-A2 Binding Deficiency for Spike Protein of SARS-CoV-2.tif by Congling Qiu (11957873)

“…Meanwhile, n-Sp1 epitope variant 5L>F significantly decreased the proportion of specific T-cell activation; n-Sp1 epitope 8L>V variant showed significantly reduced binding to HLA-A*02:01 and decreased proportion of n-Sp1-specific CD8⁺ T cell, which potentially contributes to the immune escape of SARS-CoV-2. …”

Image_2_CD8+ T-Cell Epitope Variations Suggest a Potential Antigen HLA-A2 Binding Deficiency for Spike Protein of SARS-CoV-2.tif by Congling Qiu (11957873)

“…Meanwhile, n-Sp1 epitope variant 5L>F significantly decreased the proportion of specific T-cell activation; n-Sp1 epitope 8L>V variant showed significantly reduced binding to HLA-A*02:01 and decreased proportion of n-Sp1-specific CD8⁺ T cell, which potentially contributes to the immune escape of SARS-CoV-2. …”

Diagnostic accuracy of antigen-based RDT kits for COVID-19 diagnosis/screening compared to PCR test for combined participants. by Akhere A. Omonkhua (9727333)

Diagnostic accuracy of antigen-based RDT kits for COVID-19 diagnosis/screening compared to PCR test for asymptomatic participants. by Akhere A. Omonkhua (9727333)

Evaluation process for the validation of SARS-COV-2 rapid diagnostic tests in Nigeria. by Akhere A. Omonkhua (9727333)

Sociodemographic characteristics of participants (N = 1310). by Akhere A. Omonkhua (9727333)

Diagnostic accuracy of antibody-based (IgG) RDT kits for COVID-19 diagnosis/screening compared to PCR test for combined participants. by Akhere A. Omonkhua (9727333)

Diagnostic accuracy of antibody-based (IgM) RDT kits for COVID-19 diagnosis/screening compared to PCR test for asymptomatic participants. by Akhere A. Omonkhua (9727333)

Diagnostic accuracy of antibody-based (IgM) RDT kits for COVID-19 diagnosis/screening compared to PCR test for symptomatic participants. by Akhere A. Omonkhua (9727333)

Diagnostic accuracy of antibody-based (IgG) RDT kits for COVID-19 diagnosis/screening compared to PCR test for asymptomatic participants. by Akhere A. Omonkhua (9727333)

List of PCR reagents supplied by NCDC. by Akhere A. Omonkhua (9727333)

Diagnostic accuracy of antibody-based (IgM) RDT kits for COVID-19 diagnosis/screening compared to PCR test for combined participants. by Akhere A. Omonkhua (9727333)

Flowchart for inclusion and exclusion criteria. by Akhere A. Omonkhua (9727333)

Diagnostic accuracy of antigen-based RDT kits for COVID-19 diagnosis/screening compared to PCR test for symptomatic participants. by Akhere A. Omonkhua (9727333)

List of COVID-19 rapid diagnostic test kits evaluated. by Akhere A. Omonkhua (9727333)

Clinical symptoms of the study participants (N = 1310). by Akhere A. Omonkhua (9727333)

Diagnostic accuracy of antibody-based (IgG) RDT kits for COVID-19 diagnosis/screening compared to PCR test for symptomatic participants. by Akhere A. Omonkhua (9727333)